PSORIAZIS

DOI: 10.7241/ourd.2022book.2_4

First Page (Prima pagina)

Psoriazis este diagnosticat la 1-3% din popula?ie; debutul în copilărie este raportat în 30-50% din cazuri, 2/3 din cazuri fiind forme familiale ?i, în 2-5% din cazuri debutul este înainte de vârsta de 2 ani [1]. Există multe date contradictorii referitoare la inciden?a ?i prevalen?a bolii în popula?ia pediatrică, majoritatea datelor fiind ob?inute din registre na?ionale declarative sau din rapoarte clinice. În Europa se apreciază că prevalen?a cumulată a psoriazisului înainte de vârsta de 18 ani variază între 0,5-0,7%; prevalen?a fiind de 0,37-0,55% la grupa de vârstă 0-10 ani, 1,01-1,37% la grupa de vârstă 10-18 ani [1]. Cazurile sunt mai numeroa-se în Europa decât în Asia sau Africa, iar în America cazurile de psoriazis predomină la copiii de origine europeană.
Din punct de vedere epidemiologic se disting 2 tipuri de psoriazis:
Psoriazis familial (tip I) caracterizat prin:
? debut precoce în primii ani de via?ă;
? anamneză familială pozitivă în 2/3 din cazuri;
? debut precoce la sexul feminin;
? poate fi element de diagnosticat suplimentar în cazurile incerte de diagnostic la copii.
Psoriazis sporadic (tip II) caracterizat prin:
? debut tardiv, în perioada adultă;
? anamneză familială pozitivă doar în 1/3 din cazuri;
? comorbidită?i precoce ?i numeroase.

Keywords

  • Psoriazis; Psoriazis în plăci; Psoriazis la nivelul scalpului; Psoriazis gutat; Psoriazis genital; Psoriazis la nivelul fe?ei; Psoriazis palmo-plantar; Onicopatia psoriazică; PUVA; Re-PUVA; Terapia biologică

References

1. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-6.
2. Bonigen J, Phan A, Hadj-Rabia S, et al. Impact de l?a?ge et du sexe sur les aspects cliniques et e?pide?miologiques du psoriasis de l?enfant. Donne?es d?une e?tude transversale, multicentrique franc?aise. Ann Dermatol Venereol. 2016;143:354-63.
3. Bukhari I, Ismail M, Hasan M, et al. Perspectives in psoriasis, psoriatic arthritis, non-alcoholic fatty liver disease and atherosclerosis in psoriasis. Our Dermatol Online. 2018;9:447-52.
4. Ndiaye M, Ly F, Dioussé P,et al. [The characteristics of severe forms of psoriasis on pigmented skins: A retrospective study of 102 cases in Dakar, Senagal]. Our Dermatol Online. 2017;8:138-42.
5. Mahe? E. Childhood psoriasis. Eur J Dermatol. 2016;26:537-8.
6. de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62:1013-30.
7. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-41.
8. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161-201
9. Mahe? E. Cushing?s syndrome induced by high-potency topical corticosteroids in two children with palmoplantar psoriasis taking acitretin. Pediatr Dermatol. 2017;34:219-20.
10. Sharon C, Jiquan S. Association of NLRP1 and NLRP3 gene polymorphism with psoriasis. Our Dermatol Online. 2020;11:275-83.
11. Mahe? E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis(Auckl). 2020;10:45-56.
12. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445-86.
13. Bronckers IMG, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153:1147-57.

14. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-51.
15. Papp K, Thac? i D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40-9.
16. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594-603.
17. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594-603.
18. Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1984-92.
19. Lavaud J, Mahe? E. Proactive treatment in childhood psoriasis. Ann Dermatol Venereol. 2020;147:29-35.
20. Adil M, Singh PK, Sonkar VK, et al. Omega-3 fatty acids and quality of life in psoriasis: an open, randomised controlled study. Our Dermatol Online. 2019;10:12-16.

Comments are closed.